Speaker
Mr
Jason Palazzolo
(Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia)
Description
Microbeam radiation therapy (MRT) is a promising modality for administering synchrotron-generated ionizing radiation (IR). Compared to conventionally used broadbeam (BB) radiation, MRT yields improved therapeutic benefits by preserving healthy tissues whilst selectively ablating tumours. By offering beam precision and reduced radiation scattering, the Australian Synchrotron (AS) is ideal for studying non-targeted effects of radiation, such as the bystander and abscopal effect. To establish whether these non-targeted effects depend on the immune system, C57BL/6 mice were irradiated with BB or MRT at the AS. Mice were exposed to 10Gy or 40Gy peak doses in 8x8mm or 8x1mm areas. Irradiated skin and bystander skin and intestine, were collected at 24h and 96h post-irradiation and processed immunohistochemically for apoptotic events and immune response changes in situ, compared to unirradiated control mice.
Activated macrophages and dendritic cells in irradiated skin increased up to 2.1 fold and up to 1.7 fold in bystander skin. Neutrophils increased up to 0.8 fold in irradiated skin and 2 fold in bystander skin. T-lymphocytes showed no significant changes in the irradiated skin, however, increased 2 fold in bystander skin. Apoptotic cells showed no significant changes across any tissue. Intestinal tissue yielded consistent results to bystander skin. Therefore, following pulsed radiation exposure, there is an innate immune response in IR-targeted mouse skin. Whilst, within bystander tissues, there is a response from innate and adaptive immunity. Future experiments aim to study these immune modulators in immuno-compromised mice.
| Keywords | Immunology Radiotherapy Immunity MRT IMBL Cell Biology Radiobiology |
|---|
Primary author
Mr
Jason Palazzolo
(Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia)
Co-authors
Dr
Alesia Ivashkevich
(Monash University, Department of Molecular and Translational Sciences, Clayton, VIC, Australia & Radiation Oncology, Canberra Hospital, Garran, ACT, Australia)
Dr
Andrea Smith
(Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia)
Dr
Andrew Stevenson
(CSIRO, Clayton, VIC, Australia & Australian Synchrotron, Clayton, VIC, Australia)
Dr
Carl Sprung
(Hudson Institute, Centre for Innate Immunity and Infectious Diseases, Australia & Monash University, Department of Molecular and Translational Sciences, Clayton, VIC, Australia)
Dr
Christopher Hall
(Australian Synchrotron, Clayton, VIC, Australia)
Dr
Helen Forrester
(Hudson Institute, Centre for Innate Immunity and Infectious Diseases, Australia & Monash University, Department of Molecular and Translational Sciences, Clayton, VIC, Australia)
Ms
Jessica Ventura
(Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia)
Dr
Nicole Haynes
(Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia)
Prof.
Olga Martin
(Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia & Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, VIC, Australia & Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia)
Dr
Pavel Lobachevsky
(Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia & Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, VIC, Australia)
